Cancer genomics plays a crucial role in oncology by enhancing our understanding of how genes drive cancer and facilitating the development of improved treatments. This field meticulously examines various cancers' genetic makeup through various methodologies, leading to groundbreaking discoveries. Innovative ...
& Liu, Q. Lessons learned: dose selection of small molecule-targeted oncology drugs. Clin. Cancer Res. 22, 2630–2638 (2016). Article CAS Google Scholar Waldner, M., Fantus, D., Solari, M. & Thomson, A. W. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in...
Unlike many bioanalytical services that focus on exogenous biomarkers, such as drugs or externally introduced compounds, our targeted panels are designed to quantify biomarkers intrinsic to the system being studied. Because endogenous biomarkers often exist at the lower limits of analytical detection, ...
K. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 12, 606–624 (2022). Article CAS PubMed PubMed Central Google Scholar Demidenko, E. & Miller, T. W. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS...
(A)The combination cancer therapy with random drugs sequence may be the main reason for limited success of cancer treatment. (B) The combination drug therapy with either concurrent, sequential or neoadjuvant will become more precise and effective by genome sequencing of patients and molecular classifi...
Several Trop2-targeted drugs are currently under development, including antibodies, ADCs, and combination therapies, with ADCs at the forefront of cancer therapy and precision medicine. The FDA has approved SG for the treatment of TNBC and HR+/HER2-breast cancer patients. There are several Trop2...
[97]. Overall, Allosteric or Type III inhibitors exhibit the highest degree of target kinase selectivity as they exploit binding sites and physiological mechanisms that are exclusive to a particular kinase [106]. With respect to ATP, these drugs are steady-state noncompetitive or uncompetitive ...
Fourthly, debate is ongoing over the second-line treatment strategies for patients resistant to combination therapy. Some scholars argue that targeted drugs, such as sorafenib, lenvatinib, regorafenib, cabozantinib, or ramucirumab, have similar efficacy in the second-line treatment, while others recommend...
drug efficacy and reduce drug-drug interactions.141Mobility of gut microbiota is not limited to movement within inter-individuals, but can also occur within intra-individuals due to factors such as spatial, transient, seasonal, hormonal, and nutritional changes or the presence of multiple drugs.159...
1,2,3,4,5,6,7,8,9,10 These targeted drugs function as ATP-competitive inhibitors. Additionally, inhibitors of kinases that are activated downstream of these oncoproteins have been developed for use as either monotherapy, or in combination with inhibitors of the upstream oncoprotein. The MEK1/...